• Study eval­u­ated the benefit of isatuximab in com­bi­na­tion with standard of care in prolonging pro­gres­sion free sur­vival as com­pared to standard of care in patients with re­lapsed / re­frac­tory multiple myeloma
• First ran­dom­ized Phase 3 trial to eval­u­ate the benefit of adding a mono­clonal anti­body to poma­lido­mide and dexa­meth­a­sone for treat­ment of re­lapsed / re­frac­tory multiple myeloma
• Multiple ongoing Phase 3 studies with isatuximab, an inves­ti­ga­tional agent, in com­bi­na­tion with standard of care ther­a­pies in newly diag­nosed and re­lapsed / re­frac­tory multiple myeloma

Paris, France (Press Release) – The pivotal Phase 3 trial of isatuximab in patients with re­lapsed / re­frac­tory multiple myeloma met the pri­mary end­point of prolonging pro­gres­sion free sur­vival in patients treated with isatuximab in com­bi­na­tion with poma­lido­mide and low-dose dexa­meth­a­sone versus poma­lido­mide and low-dose dexa­meth­a­sone alone (standard of care).

Results will be sub­mitted to an upcoming medical meeting and are antic­i­pated to form the basis of regu­la­tory sub­missions planned for later this year.

"We are ex­cited by these results, …

Die Jahrestagung der amerikanischen Gesellschaft für Klinische Onkologie (ASCO) hat letzten Freitagmorgen begonnen und wird bis Dienstag, den 7. Juni, dauern.

Jeden Tag finden Vorträge über das multiple Myelom statt. Freitag wurden die meisten Vorträge mit neuen Forschungsergebnissen über das Myelom gehalten. Es gab neun Vorträge während einer einzelnen Nachmittagssitzung, die sich auf das multiple Myelom konzentrierten.

Außerdem gab es am Samstag, Sonntag und Montag Fortbildungssitzungen über das multiple Myelom. Darüber hinaus gab es am Sonntag eine Sitzung mit sogenannten late-braking abstracts (hochaktuellen Zusammenfassungen), die eine Präsentation über wichtige, neue Forschungsergebnisse über …

The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is now history, but there's still plenty of news to report from the meeting.

In this edition of the Beacon's ASCO multiple myeloma updates, the focus is on pre­sen­ta­tions that took place the last two days of the ASCO meet­ing – this past Monday and Tuesday – and which con­cerned poten­tial new multiple myeloma ther­a­pies.

There was a block of oral pre­sen­ta­tions related to poten­tial new myeloma ther­a­pies that took place Tuesday morning, and all those pre­sen­ta­tions are covered in this article. …

This year’s American Society of Clinical Oncology (ASCO) annual meeting began the morning of last Friday, and the meeting will run through Tues­day.

Multiple myeloma-related pre­sen­ta­tions are taking place every day of the meeting. Friday, how­ever, was the busiest day at the meeting in terms of oral pre­sen­ta­tions with new myeloma-related re­search. There were nine such pre­sen­ta­tions during a single afternoon session focused on multiple myeloma.

In addi­tion, there were myeloma-related education session pre­sen­ta­tions on Saturday, yesterday, and today. There also was a late-breaking ab­stract session yesterday (Sunday) with one pre­sen­ta­tion that …

We hope you had a pleasant Wednesday, myeloma world.

Our Wednesday was going full steam ahead until modern tech­nology at Myeloma Morning Headquarters decided to take a vaca­tion. And this had to hap­pen, of course, on a day when we have some particularly in­ter­est­ing devel­op­ments to discuss.

What “developments” might those be, you ask?

Well, those “developments” would be the titles of all pre­sen­ta­tions to be given at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The titles were made public on Wednesday.

In this edition of

A new year is upon us.  I hope it has started well for everybody, and that all had a great holiday season!

The last few weeks of 2014 were a hap­pen­ing time for the mul­ti­ple myeloma com­munity. The short span of time witnessed the pub­li­ca­tion of up­dated criteria for the diag­nosis of mul­ti­ple myeloma from the Inter­na­tional Myeloma Work­ing Group (IMWG). In addi­tion, the 56^th annual meeting of the American Society of He­ma­tol­ogy (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster pre­sen­ta­tions.

Therefore, it is again …

This past Sunday was the second day of the American Society of Hema­tology’s (ASH) annual meeting, which was held in San Francisco.

As on the first day of the meeting, myeloma-related pre­sen­ta­tions once again took place during several sessions through­out the day.

A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.

While the education session was being held, a separate “scientific sym­po­sium” with two oral pre­sen­ta­tions took place in parallel.  The session focused on a novel immuno­therapeutic ap­proach to treating cancer known as …